Review of Pharmacoeconomic Studies of Adalimumab in the Rheumatoid Arthritis Management
- Author:
Yue-Hua LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: Adalimumab; Cost; Pharmacoeconomics; Rheumatoid arthritis
- From: Chinese Pharmaceutical Journal 2017;52(10):886-890
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To summarize the pharmacoeconomic studies of adalimumab in the management of Rheumatoid Arthritis, discuss the cost-effectiveness and adverse reaction of combination use of adalimumab and DMARDs, and compare the economic values of TNF-α inhibitors. METHODS: Search Pubmed and MedLINE for pharmacoeconomics studies of adalimumab using in the treatment of RA. All the results are systematically summarized and assessed. RESULTS: Seven studies on pharmacoeconomics assessment of adalimumab were selected and discussed. Compared with conventional DMARDs, adalimumab costs more but obviously extends the QALYs of RA patients. Adalimumab also provides significant improvement in symptom severity with less adverse reaction. The efficacy of combination use of adalimumab and MTX is better than adalimumab alone. In terms of cost and effectiveness, adalimumab has advantages over infliximab and is equal to etanercept. CONCLUSION: Though adalimumab costs higher for the RA patients, it can significantly improve the quality of life when in the combination treatment with DMARDs, as well as reduce adverse reactions. Compared with other TNF-α inhibitors, adalimumab shows superiority both in efficacy and cost. Thus, adalimumab is recommended for RA patients that don't respond to DMARDs.
